secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001386570-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M
--------------------------------------------------------------------------------

- Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
- Q4 net sales $33.8M (+16% YoY); Q4 net income $4.1M vs $7.2M prior; Q4 adjusted EBITDA $4.1M (+$0.7M).
- Gross margin improved 250 bps to 64.3% for year; cash $64.8M at Dec 31, 2025.
- FY 2026 net sales outlook 10-15% growth ex. reference standards segment sold in Feb 2026 for ~$6M.
- Acquired foundational NR patent portfolio from Queen’s University Belfast (Dec 2025); launched Tru Niagen Beauty (Nov 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000014/0001386570-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000014/cdxc-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001386570-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer